Short Interest in Cingulate Inc. (NASDAQ:CING) Decreases By 22.4%
Short Interest in Cingulate Inc. (NASDAQ:CING) Decreases By 22.4%
Cingulate Inc. (NASDAQ:CING – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 82,100 shares, a decline of 22.4% from the December 15th total of 105,800 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 50,600 shares, the short-interest ratio is presently 1.6 days.
納斯達克(CDH：Cing-Get Rating)12月份空頭股數股價大幅下跌。截至12月30日，空頭股數共有82,100股，較12月15日的105,800股下降了22.4%。目前，該公司1.1%的股份被賣空。以日均成交量50,600股計算，目前短息比率為1.6天。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of equities analysts have weighed in on the stock. Ascendiant Capital Markets assumed coverage on shares of Cingulate in a research report on Monday, October 3rd. They set a "buy" rating for the company. HC Wainwright reiterated a "buy" rating on shares of Cingulate in a research report on Tuesday. Finally, Maxim Group assumed coverage on shares of Cingulate in a research report on Tuesday, November 22nd. They issued a "buy" rating for the company.
許多股票分析師對該股進行了加碼。上升資本市場在10月3日星期一的一份研究報告中對Cingate的股票進行了報道。他們為該公司設定了“買入”評級。週二，HC Wainwright在一份研究報告中重申了對cingate股票的“買入”評級。最後，Maxim Group在11月22日星期二的一份研究報告中對Cingate的股票進行了報道。他們對該公司的評級為“買入”。
Insider Activity at Cingulate
Cingate的內幕活動
In other news, Director Peter J. Werth bought 28,934 shares of the firm's stock in a transaction that occurred on Tuesday, December 13th. The stock was purchased at an average cost of $0.98 per share, for a total transaction of $28,355.32. Following the purchase, the director now directly owns 975,165 shares in the company, valued at approximately $955,661.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Gregg Wm Givens acquired 85,000 shares of Cingulate stock in a transaction on Tuesday, November 22nd. The stock was bought at an average cost of $0.88 per share, for a total transaction of $74,800.00. Following the completion of the transaction, the director now owns 154,318 shares of the company's stock, valued at approximately $135,799.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Peter J. Werth acquired 28,934 shares of Cingulate stock in a transaction on Tuesday, December 13th. The shares were bought at an average price of $0.98 per share, with a total value of $28,355.32. Following the completion of the transaction, the director now directly owns 975,165 shares of the company's stock, valued at approximately $955,661.70. The disclosure for this purchase can be found here. Insiders bought a total of 141,388 shares of company stock worth $129,998 in the last three months. Company insiders own 31.28% of the company's stock.
其他新聞方面，董事彼得·韋斯在12月13日(星期二)的一筆交易中購買了28,934股該公司股票。這隻股票是以每股0.98美元的平均成本購買的，總交易額為28,355.32美元。收購完成後，董事現在直接擁有該公司975,165股票，價值約955,661.70美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過此超鏈接。在相關新聞中，董事Gregg Wm Givens在11月22日(星期二)的一筆交易中收購了85,000股彩虹股票。這隻股票的平均價格為每股0.88美元，總成交額為74,800.00美元。交易完成後，董事現在擁有該公司154,318股股票，價值約135,799.84美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接。此外，董事彼得·J·韋斯在12月13日(星期二)的一次交易中收購了28,934股彩虹股票。這些股票是以每股0.98美元的平均價格購買的，總價值為28,355.32美元。交易完成後，董事現在直接擁有975,165股該公司股票，價值約955,661.70美元。關於這次購買的披露可以找到這裏。在過去的三個月裏，內部人士總共購買了141,388股公司股票，價值129,998美元。公司內部人士持有該公司31.28%的股份。
Institutional Trading of Cingulate
扣帶的機構性交易
Cingulate Price Performance
扣帶性價比
Shares of CING traded up $0.03 during mid-day trading on Friday, reaching $0.98. The stock had a trading volume of 45,234 shares, compared to its average volume of 72,641. Cingulate has a 52-week low of $0.66 and a 52-week high of $2.48. The business's fifty day moving average is $0.96 and its 200 day moving average is $1.21. The firm has a market cap of $11.03 million and a price-to-earnings ratio of -0.66.
在週五午盤交易中，CING的股價上漲了0.03美元，達到0.98美元。該股成交量為45,234股，而其平均成交量為72,641股。Cingate的52周低點為0.66美元，52周高位為2.48美元。該業務的50日移動均線切入位為0.96美元，200日移動均線切入位為1.21美元。該公司市值為1103萬美元，市盈率為-0.66倍。
Cingulate (NASDAQ:CING – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The company reported ($0.36) earnings per share (EPS) for the quarter.
納斯達克(納斯達克：Cing-Get Rating)最近一次發佈季度收益報告是在11月14日(週一)。該公司公佈了該季度每股收益(EPS)(0.36美元)。
About Cingulate
關於扣帶
(Get Rating)
(獲取評級)
Cingulate Inc, a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders.
Cingate Inc.是一家臨牀階段的生物製藥公司，專注於開發治療注意力缺陷/多動障礙的候選產品。該公司的主要候選產品是處於第三階段臨牀試驗的CTX-1301(醋酸地塞米酯)和用於治療注意力缺陷/多動障礙的CTX-1302(右旋苯丙胺)。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Cingulate (CING)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免費獲取StockNews.com關於Cingate的研究報告(CING)
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車？
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票：在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
接受《扣帶日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cingate及相關公司的最新新聞和分析師評級的每日簡要摘要。